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Abstract
Preterm birth has the highest mortality and morbidity of all pregnancy complications. The burden of preterm birth
on public health worldwide is enormous, yet there are few effective means to prevent a preterm delivery. To date,
much of its etiology is unexplained, but genetic predisposition is thought to play a major role. In the upcoming year,
the international Preterm Birth Genome Project (PGP) consortium plans to publish a large genome wide association
study in early preterm birth. Genome-wide association studies (GWAS) are designed to identify common genetic
variants that influence health and disease. Despite the many challenges that are involved, GWAS can be an important
discovery tool, revealing genetic variations that are associated with preterm birth. It is highly unlikely that findings of
a GWAS can be directly translated into clinical practice in the short run. Nonetheless, it will help us to better
understand the etiology of preterm birth and the GWAS results will generate new hypotheses for further research,
thus enhancing our understanding of preterm birth and informing prevention efforts in the long run.
Introduction
In the upcoming year, the Preterm Birth Genome Project
(PGP), an international consortium of investigators exam-
ining the genetics of preterm birth [1], plans to publish
results of a large genome-wide association study (GWAS)
in preterm birth. The product of much time and effort,
such research promises to deliver substantial health bene-
fits for women and families. However, results of a GWAS
do not instantly translate into clinical applications that will
improve birth outcomes and ultimately maternal child
health. The translation of gene discovery into improved
health outcomes is a process [2]. This paper will provide a
brief overview describing the design and interpretation of
a GWAS and then explore the implications for the practi-
cing obstetrician gynaecologist.
Goal of a genome-wide association study
Genome-wide association studies are designed to identify
common genetic variations that are associated with certain
health outcomes or diseases. Unlike the search for highly
penetrant disease-causing gene mutations such as those
underlying sickle cell anaemia and Tay-Sachs disease,
GWAS attempt to identify single nucleotide polymorph-
isms, also known as SNPs, that are not strictly disease
causing but rather increase or decrease one’s risk of dis-
ease. Highly penetrant genetic disorders are caused by a
single mutation or a few genetic variants at most, whereas
complex or multifactorial diseases are influenced by many
genetic variants as well as environmental factors. Thus a
GWAS is inherently searching for genetic variation that
does not fit the model of a rare mutation leading to disease;
rather it is searching to identify common genetic variation
that contributes to the risk for disease. Such an endeavour
adds many layers of complexity in terms of both carrying
out GWAS as well as interpreting the results.
Of the three billion base pairs of the haploid human
genome, several million contain individual DNA sequence
variants or alleles [3]. SNPs are the most common varia-
tions in the genome with an estimated 10 million SNPs
occurring in the human population. A SNP is simply a sin-
gle base pair substitution at a particular locus (location)
and humans have approximately 1 SNP per 300 base pairs
in their genome [4]. Very interestingly, human beings
differ from one another in their genetic make-up only by
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0.1%. However, in this 0.1% of the genome lie key differ-
ences that can determine a person’s susceptibility to dis-
eases or health outcomes such as preterm birth. While
pregnancy is not a disease, adverse birth outcomes such as
preterm birth or stillbirth will be considered as disease
states for the purposes of this paper.
The goal of a GWAS is to identify particular SNPs in the
genome that are associated with increased risk for or
protection from disease. Common variation is generally
present in greater than one percent of the population [5].
As mentioned earlier, this variation is not highly penetrant
nor directly causes disease, but rather confers susceptibil-
ity or protection. The benefits of a GWAS are that one
does not need a hypothesis as to which genes or which
pathways are involved in the causation of the disease; the
approach is hypothesis free. This can prove extremely
useful in challenging arenas such as preterm birth where
the etiology and mechanism of the condition remain elu-
sive [6]. But it also means that results are not final
answers. A SNP identified in a GWAS may not be the
actual SNP that is causing the disease in question but
rather it may be near or in linkage disequilibrium (LD)
with the SNP that leads to a functional change. LD is the
non-random association of alleles at two or more loci and
it describes a situation in which some combinations of
alleles or genetic markers occur more or less frequently
together in a population than would be expected.
The results of a GWAS provide a mechanism for gener-
ating further hypotheses to better understand biology,
pathophysiology and disease causation. They provide a clue
as to where to look amongst the more than three billion
base pairs making up the genome to identify important
genetic regions, genes, and potential mechanisms. Several
publicly available databases exist that list all GWAS studies
and their findings published to date (Table 1).
Genotyping
DNA for a GWAS can be collected from multiple
sources. These include maternal and/or fetal blood, saliva
and blood spots. Commercially available high-throughput
genotyping platforms (Affymetrix and Illumina) are used
for the genotyping of genomic DNA. Currently, these
so-called SNP arrays can genotype over 5 million SNPs at
the same time. SNP assays rely on the biochemical prin-
ciple that nucleotide bases bind to their complementary
bases (adenine binds to thymine and cytosine binds
to guanine) [7]. Fragmented single-stranded DNA is
hybridized to arrays containing up to 1 million unique
nucleotide probe sequences. Each probe is designed to
bind to a target DNA. Subsequently, the intensity of the
signal associated with each probe and its target after
hybridization is measured. This signal intensity is depen-
dent upon the amount of target DNA in the sample, and
the affinity between target DNA and probe. Clustering
algorithms are then used to infer SNP genotypes from
the intensity of the allele-specific probes.
One important concept to consider is linkage disequili-
brium or LD. As mentioned previously, this is the non-
random association of alleles at two or more loci. Certain
combinations of alleles or genetic markers occur more or
less frequently together in a population than would be
expected from a random formation of haplotypes (series
of SNPs close together in the genome) from alleles based
on their frequencies. Two SNPs that are in strong LD may
therefore serve as proxies for one another: genotyping one
of the SNPs gives nearly complete information regarding
the genotype of the other SNP. This explains why an array
that genotypes 5 million SNPs effectively actually assays a
larger proportion of human genetic variation than repre-
sented on the array. For maximum advantage, the current
arrays are specifically designed to detect SNPs that corre-
late with, or tag, a large number of other SNPs in the
human genome. The work of the International HapMap
Project largely facilitated this concept [8]. General differ-
ences in the LD patterns among different populations
exist and this can influence the SNPs that are selected to
be genotyped in a GWAS.
Genetics of preterm birth
Preterm birth is defined as birth before 37 completed
weeks of gestation (WHO guidelines) and its rate has risen
alarmingly over the past twenty years. After peaking in
2006 at 12.8, the preterm birth rate in the United States
was reported at 12.2% in 2009, the most recent year for
which data are available [9]. Among African Americans,
the preterm birth rate in 2009 was 17.5%. Other developed
countries also have shown rising preterm birth rates in the
past decade [10-12]. Possible explanations for these high
rates include the increases in multiple births, older mater-
nal age, elective caesarean sections before 37 weeks
of gestation, and the use of assisted reproductive technolo-
gies such as in vitro fertilization. However, the rise in
preterm birth can only be partially attributed to these
factors [13].
Table 1 GWAS Resources
Source URL
Catalog of Genome Wide Association Studies
National Human Genome Research Institute
http://www.genome.gov/26525384
GWAS Central – A Genotype-Phenotype Association Database http://databib.org/repository/543
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The majority of preterm deliveries are idiopathic
preterm births and preterm births due to preterm prema-
ture rupture of fetal membranes. In both cases, much of
the etiology is unknown [14]. While many environmental
contributors to preterm birth such as stress, smoking, and
inflammation, are identified, a large body of research sug-
gests that genetic predisposition plays an important role,
as reviewed by Dolan et al. [15]. The leading risk factor for
a preterm delivery is a prior pregnancy resulting in
preterm birth. Next to cervical length measurement, this is
currently the single best predictor of preterm birth in
multiparous women. Twin studies support the role of
genetic risk factors in preterm birth by estimating the her-
itability at 20 to 40 percent [16,17]. Furthermore, mothers
who were born preterm themselves have an increased risk
of delivering their babies preterm [18]. Evidence also
shows there is a large racial disparity in the etiology of pre-
term birth. The association between ethnicity, especially
African ancestry, and preterm birth persists even if
corrected for other risk factors such as socio-economic
status and access to prenatal care. While evidence does
not suggest that preterm birth is inherited in a classic
Mendelian autosomal recessive or autosomal dominant
fashion, a predisposition to preterm birth clearly runs in
families. Therefore, GWAS will likely be a useful tool to
identify the genetic contribution to preterm birth that
influences this heritability.
Design of a GWAS for preterm birth
The most common design of a GWAS is a case-control
study in which a large number of DNA samples from
cases and controls are analyzed to look for SNPs that are
associated with the disease or condition under study.
A generally accepted sample size of 1000 cases and 1000
controls is likely adequate for many GWAS, however the
required sample size depends on many factors including
the prevalence of the disease and the effect size of the
alleles. As in any case-control study, most important to
the success of the study is selecting cases that meet a stan-
dard and consistent definition of the condition under
study. This is a particularly challenging issue in preterm
birth research as the phenotype of preterm birth can be
quite complex to define. At its simplest definition, preterm
birth is defined by the World Health Organization as birth
before 37 weeks gestation. But beyond that, the definition
becomes much more complex. Is late preterm birth,
defined as 34 0/7 to 36 6/7 weeks, the same phenotype as
very preterm birth at < 32 weeks? Is a preterm birth that
follows chorioamnionitis and preterm premature rupture
of the membranes the same phenotype as a preterm birth
that follows preeclampsia and a placental abruption, even
if they both occur at 28 weeks gestation? While challen-
ging for preterm birth researchers, the goal is to identify
as clear and consistent a phenotype as possible. For the
purposes of many studies, spontaneous singleton preterm
birth is the phenotype of interest and thus multiple
gestations, fetuses with birth defects, and major maternal
medical complications such as hypertension are excluded.
Selection of controls must be carried out such that
controls come from the same population as the cases and
they must be similar in every way to the cases other than
the occurrence of the disease. This is generally accom-
plished by identifying term controls from the same labour
and delivery floors where the cases are identified. Further-
more, it is important that as much demographic and
environmental risk data are collected about the study
subjects, so that they can be considered and controlled for
in the final analyses.
Challenges in interpretation and translation of
findings
The use of genome wide analysis is a very powerful
research tool. It can be an important first step in disco-
vering the genetic variations that are associated with
preterm birth. Analytic challenges in the interpretation
of findings from GWAS however require technical and
analytic expertise and software designed to carry out
such analyses [19,20]. The fact that GWAS are looking
to identify common genetic variation associated with
small effect sizes requires large study samples (at least
1000 cases and 1000 controls), which often leads to con-
sortia coming together to pool data. Working with large
teams to assure consistent phenotyping, accurate geno-
typing, and standard protocols across the study sites can
be challenging, as well.
There are many challenges to interpreting the findings
of a GWAS. Significant findings need to be interpreted in
the context of the million comparisons that occur in a
GWAS. In order to handle the multiple comparisons, a
p-value of less than 5 x 10 -8 is considered significant in a
GWAS. This p-value threshold is for 1 million SNPs. It
roughly approximates a p-value of less than 0.05 (equal to
a 1 in 20 likelihood that the finding was due to chance
alone) when doing one million comparisons. Mathemati-
cally, this can be calculated as 0.05 / 1,000,000 = 5 x 10 -8.
This is known as a Bonferroni correction, a conservative
statistical method to counteract the problem of type I
error (false positives) in multiple comparisons.
Population stratification is another major challenge in
interpreting GWAS. Population stratification captures the
idea that the study identifies a variant (SNP) associated
with a characteristic of a population that is associated with
the disease, not the disease itself. The SNP of study may
have significantly different allele frequencies in two differ-
ent populations and the frequency of these populations
may differ between the case and control group. This
induces an association of the SNP with case-control status
when it is actually only associated with the population
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differences between cases and controls. One way to assure
that the association between the genetic variant and the
disease outcome is actually robust, therefore, is to replicate
the finding in a second study of subjects from a different
racial / ethnic background. Many journals indeed require
replication of findings before publishing GWAS. In addi-
tion, computational methods are also available to correct
for population stratification in the analysis of a GWAS.
Thus far, most GWAS are conducted in populations from
European descent. It is important to select a strict and
consistent phenotype, and therefore the choice of one par-
ticular population is often made. Whether the findings of
many of these studies are generalizable to non-European
populations is largely unknown.
In complex conditions like preterm birth that are known
to be multifactorial, which means they are influenced by
both genetic and environmental factors, GWAS will likely
only tell part of the story. Demographic and environmen-
tal factors may be as important as genetic factors in the
etiology of preterm birth. The question remains therefore,
how can we best integrate environmental data such as
smoking data and stress with the GWAS findings? And
what if, as in the case of human height where 20 SNPs
where found to explain only approximately three percent
of the variation in human height [21], genetic variation is
found to explain only a small amount of the variation in
the risk of preterm birth? This is an area where continued
research is needed. As Wang et al. illustrate, one model
for using gene environment interactions is targeting
environmental interventions such as smoking cessation
programs to individuals with specific genetic variants [22].
Studying pregnancy adds another layer of complexity:
there are two patients – mother and newborn – and three
genomes to consider: the maternal, paternal and child’s.
Integrating genome wide data across three individuals in
order to identify the etiology of a complex birth outcome
such as preterm birth is a challenge that continues to
require new methodologies and continued research.
Implications of GWAS for the clinician
We are hopeful that GWAS will identify regions of the
genome associated with preterm birth. They can then
serve as a useful tool for researchers to learn more about
the basic pathophysiology of preterm birth and the path-
ways leading to preterm labor. Furthermore, as in the case
of many complex disease conditions, there is the promise
that risk prediction profiles could be identified in which a
number of genetic variants in the aggregate can help assess
risk [23]. While this is not a short-term proposition, it
provides a roadmap for research to understand who is at
risk for or protected against preterm birth.
GWAS will not lower rates of preterm birth in the short
run. In fact, some critics of GWAS suggest that they have
not provided as much information as was hoped. Critics
suggest that the genetic variation underpinning many
disease states will be found by identifying in a number of
rare variants, not common variants, and thus inquiry via
GWAS will not likely lead to useful information [19,24].
But, in the case of some conditions such as Alzheimer’s
disease and breast cancer, genetic variants have been iden-
tified that will likely serve useful roles in the development
of risk prediction algorithms and targeted treatment.
What is clear, however, is that GWAS in the area of
preterm birth will add new information regarding genetic
variation and risk to the research arena surrounding
preterm birth. They will likely help us learn more about
the fundamental biology of preterm birth and the biology
of its causation, not its symptoms. GWAS will contribute
to our ability to assess personalized risk for preterm birth
and hopefully guide pharmacogenomic interventions. In
an area such as preterm birth, where the public health
burden is tremendous and the clinical interventions are
scarce, GWAS will enhance scientific inquiry by providing
new ideas and data in an area that is rich for discovery.
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